Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents.
Journal Article
Dias, N., Goossens, J., Baldeyrou, B., Lansiaux, A., Colson, P., Di Salvo, A., …Bailly, C. (2005)
Oxoazabenzo[de]anthracenes conjugated to Amino Acids: Synthesis and evaluation as DNA-binding antitumor agents. Bioconjugate Chemistry, 16(4), 949-958. https://doi.org/10.1021/bc050065x
We report the synthesis of an original series of oxoazabenzo[de]anthracenes conjugated to an amino acid: Ala, Phe, Pro, Lys, or Gly (4a-e, respectively). The compounds, derive...
Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model
Journal Article
Van Valckenborgh, E., Mincher, D., Di Salvo, A., Van Riet, I., Young, L., Van Camp, B., & Vanderkerken, K. (2005)
Targeting an MMP-9-activated prodrug to multiple myeloma-diseased bone marrow: a proof of principle in the 5T33MM mouse model. Leukemia, 19(9), 1628-1633. https://doi.org/10.1038/sj.leu.2403866
Multiple myeloma (MM) is an incurable B-cell cancer characterised by the monoclonal proliferation of tumour cells in the bone marrow (BM). It has been described that matrix me...
Anthracene derivatives as anti-cancer agents.
Patent
Mincher, D. & Turnbull, A. (2004)
Anthracene derivatives as anti-cancer agents.
The present invention relates to compounds which are based on an anthraquinone nucleus for use in medicine, particularly as anti-cancer agents which exert their effects throug...